AML patients with a nucleophosmin-1 mutation (NPM1mut) are recognized as a separate entity by the World Health Organization (WHO) [12,13], since NPM1mut is a founder genetic event that is rare in MDS [14] with distinct genetic, pathological, immunophenotypic, and clinical characteristics (Table 1). The gene discussed is NPM1; the disease is acute myeloid leukemia.